96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial-Reference-Cited by-同舟云学术

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

Published:2024-05 Issue: Volume:127 Page:104390
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Farrell Michael^ORCID,Shahbazi Jeyran,Chambers Mark,Byrne Marianne,Gholami Jaleh,Zahra Emma^ORCID,Grebely Jason^ORCID,Lintzeris Nicholas,Larance Briony,Ali Robert,Nielsen Suzanne^ORCID,Dunlop Adrian^ORCID,Dore Gregory J.,McDonough Michael,Montebello Mark^ORCID,Weiss Rob,Rodgers Craig^ORCID,Cook Jon,Degenhardt Louisa^ORCID

Funder

National Health and Medical Research Council

National Institute on Drug Abuse

National Institutes of Health

National Drug and Alcohol Research Centre

Department of Health and Ageing, Australian Government

Indivior PLC

Publisher

Elsevier BV

Reference49 articles.

1. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis;Andorn;Journal of Clinical Psychopharmacology,2020

2. Scoring - Psychometric (unweighted) or Utility (weighted)?,2014

3. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health and Quality of Life Outcomes,2004

4. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia;Barnett;Drug and Alcohol Dependence,2021

5. Continued posttrial benefits of buprenorphine extended release: Recover study findings;Boyett;Journal of Addiction Medicine,2023